aspartic acid has been researched along with Hepatitis C, Chronic in 8 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The enhanced liver fibrosis (ELF) index is a highly sensitive noninvasive marker of hepatic fibrosis that has had limited assessment in the HIV/HCV population." | 1.62 | The Enhanced Liver Fibrosis Index Predicts Hepatic Fibrosis Superior to FIB4 and APRI in HIV/HCV Infected Patients. ( Abdel-Hameed, EA; Kottilil, S; Rouster, SD; Sherman, KE, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Hameed, EA | 1 |
| Rouster, SD | 1 |
| Kottilil, S | 1 |
| Sherman, KE | 1 |
| El Aggan, H | 1 |
| Farahat, N | 1 |
| El Deeb, N | 1 |
| Zeid, A | 1 |
| El-Shendidi, A | 1 |
| Bladowska, J | 1 |
| Zimny, A | 1 |
| Knysz, B | 1 |
| Małyszczak, K | 1 |
| Kołtowska, A | 1 |
| Szewczyk, P | 1 |
| Gąsiorowski, J | 1 |
| Furdal, M | 1 |
| Sąsiadek, MJ | 1 |
| Pattullo, V | 1 |
| McAndrews, MP | 1 |
| Damyanovich, A | 1 |
| Heathcote, EJ | 1 |
| Byrnes, V | 1 |
| Miller, A | 1 |
| Lowry, D | 1 |
| Hill, E | 1 |
| Weinstein, C | 1 |
| Alsop, D | 1 |
| Lenkinski, R | 1 |
| Afdhal, NH | 1 |
| Ferraioli, G | 1 |
| Tinelli, C | 1 |
| Malfitano, A | 1 |
| Dal Bello, B | 1 |
| Filice, G | 1 |
| Filice, C | 1 |
| Above, E | 1 |
| Barbarini, G | 1 |
| Brunetti, E | 1 |
| Calderon, W | 1 |
| Di Gregorio, M | 1 |
| Lissandrin, R | 1 |
| Ludovisi, S | 1 |
| Maiocchi, L | 1 |
| Michelone, G | 1 |
| Mondelli, M | 1 |
| Patruno, SF | 1 |
| Perretti, A | 1 |
| Poma, G | 1 |
| Sacchi, P | 1 |
| Zaramella, M | 1 |
| Zicchetti, M | 1 |
| Assy, N | 1 |
| Minuk, GY | 1 |
| Shiono, Y | 1 |
| Ikeda, R | 1 |
| Hayashi, H | 1 |
| Wakusawa, S | 1 |
| Sanae, F | 1 |
| Takikawa, T | 1 |
| Imaizumi, Y | 1 |
| Yano, M | 1 |
| Yoshioka, K | 1 |
| Kawanaka, M | 1 |
| Yamada, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents.[NCT02745132] | Phase 4 | 80 participants (Anticipated) | Interventional | 2016-06-30 | Not yet recruiting | ||
| A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects[NCT00136214] | 22 participants (Actual) | Observational | 2004-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A battery of pen and paper neurocognitive tests where subject means are reported compared to the normative Z score. Data is reported at baseline (T1), week 12 on treatment (T2) and 12 weeks after treatment (week 60, T3). Improvements are increases in the test result compared to baseline as determined against the Z score. tests performed included Hopkins learning trials (HVLT), a measure of of verbal learning and memory and the Roy-Osterrieth Complex figure test (ROCF) which evaluates visio-spatal abilities, memory, planning and working memory. Improvements in the score (increases in value compared, either less negative or more positive to the Z score) shown in the table are reflective of improvements in these neurocognitive parameters. (NCT00136214)
Timeframe: 18 months overall with measures performed at baseline (T1), week 12 (T2) and 12 weeks after end of treatment (T3) with PEG-IFN for 48 weeks which is 60 weeks post baseline and only done in treated group and not controls
| Intervention | Z-score (Mean) | |||||
|---|---|---|---|---|---|---|
| HVLT, Verbal Learning Total, T1 | HVLT, Verbal Learning Total, T2 | HVLT, Verbal Learning Total, T3 | ROCF, T1 | ROCF, T2 | ROCF,T3 | |
| Interferon Treated Group | -1.43 | -0.78 | -0.7 | 0.34 | 0.15 | 0.33 |
| Non-treated Cohort Control | -2.0 | -1.16 | NA | -1.0 | 0.05 | NA |
Evaluation of changes in MR spectroscopy. reductions in ratio of Cho and MI reflect improvements in cerebral inflammation and improvement in cognition. Increases in the NAA ratio are suggestive of improvement in cognitive function. (NCT00136214)
Timeframe: 18 months overall with measures performed at baseline (T1), week 12 (T2) and 12 weeks after end of treatment (T3) with PEG-IFN for 48 weeks which is 60 weeks post baseline
| Intervention | ratio (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basal Ganglia, T1, Cho/Cr | Basal Ganglia,T2, Cho/Cr | Basal Ganglia, T3, Cho/Cr | Basal Ganglia, T1, MI/Cr | Basal Ganglia T2. MI/C | Basal Ganglia T3, MI/C | Frontal Cortex T1, Cho/Cr | Frontal Cortex T2, Cho/Cr | Frontal Cortex T3, Cho/Cr | Basal Ganglia T1, NAA/Cr | Basal Ganglia T2, NAA/Cr | Basal Ganglia T3, NAA/Cr | Frontal Cortex T1,Mi/Cr | Frontal Cortex T2, MI/Cr | Frontal Cortex T3, MI/Cr | Frontal Cortex T1, NAA/Cr | Frontal Cortex T2, NAA/Cr | Frontal Cortex T3, NAA/Cr | DLPFC T1, Cho/Cr | DLPFC T2, Cho/Cr | DLPFC T3, Cho/Cr | DLPFC T1, MI/Cr | DLPFC T2, MI/Cr | DLPFC T3/ MI/Cr | DLPFC T1, NAA/Cr | DLPFC T2, NAA/Cr | DLFPC T3, NAA/Cr | |
| Interferon Treated Group | 0.42 | 0.28 | 0.34 | 0.78 | 0.71 | 0.75 | 0.29 | 0.26 | 0.29 | 1.26 | 1.25 | 1.09 | 0.68 | 0.75 | 0.71 | 1.73 | 1.74 | 1.75 | 0.31 | 0.25 | 0.26 | 0.79 | 0.75 | 0.93 | 1.72 | 1.65 | 1.78 |
| Non-treated Cohort Control | 0.30 | 0.28 | NA | 0.78 | 0.72 | NA | 0.28 | 0.29 | NA | 1.28 | 1.07 | NA | 0.77 | 1.19 | NA | 1.55 | 1.72 | NA | 0.27 | 0.27 | NA | 0.78 | 0.86 | NA | 1.61 | 1.60 | NA |
1 trial available for aspartic acid and Hepatitis C, Chronic
| Article | Year |
|---|---|
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
7 other studies available for aspartic acid and Hepatitis C, Chronic
| Article | Year |
|---|---|
The Enhanced Liver Fibrosis Index Predicts Hepatic Fibrosis Superior to FIB4 and APRI in HIV/HCV Infected Patients.
Topics: Aspartate Aminotransferases; Aspartic Acid; Biomarkers; Hepacivirus; Hepatitis C; Hepatitis C, Chron | 2021 |
Peripheral blood and hepatic Toll-like receptor 7 expression and interferon lambda 1 levels in chronic hepatitis C: Relation to virus replication and liver injury.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartic Acid; Biomarkers; Cytokines; Egypt; Female; | 2019 |
Evaluation of early cerebral metabolic, perfusion and microstructural changes in HCV-positive patients: a pilot study.
Topics: Adult; Aspartic Acid; Blood Volume; Brain; Brain Diseases; Case-Control Studies; Cerebrovascular Cir | 2013 |
Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes.
Topics: Aspartic Acid; Brain; Cognition Disorders; Cohort Studies; Creatine; Fatigue; Female; Globus Pallidu | 2011 |
Performance of real-time strain elastography, transient elastography, and aspartate-to-platelet ratio index in the assessment of fibrosis in chronic hepatitis C.
Topics: Adult; Area Under Curve; Aspartic Acid; Biopsy; Blood Platelets; Disease Progression; Elasticity Ima | 2012 |
Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults.
Topics: Adult; Alanine Transaminase; Aspartic Acid; Female; Fibrosis; Forecasting; Hepatitis C, Chronic; Hum | 2000 |
C282Y and H63D mutations in the HFE gene have no effect on iron overload disorders in Japan.
Topics: Adult; Asian People; Aspartic Acid; Cysteine; Female; Hemochromatosis; Hemochromatosis Protein; Hepa | 2001 |